Advertisement

Pediatric Nephrology

, Volume 21, Issue 5, pp 719–724 | Cite as

The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients

  • Giovanni MontiniEmail author
  • Francesca Ujka
  • Cristina Varagnolo
  • Luciana Ghio
  • Fabrizio Ginevri
  • Luisa Murer
  • Basile S. Thafam
  • Carla Carasi
  • Graziella Zacchello
  • Mario Plebani
Original Article

Abstract

The aims of our trial were to study the pharmacokinetics of tacrolimus in paediatric kidney transplant recipients. The study comprised 25 patients (median age 13 years, range 2–20 years) followed for 12 months; five pharmacokinetics profiles (within the first and second week and after 1 month, 6 months and 12 months) were obtained. Patients were divided into two groups: six children <6 years old and 19 older children. Tacrolimus was given at an initial dose of 0.15 mg/kg twice a day. Blood samples were drawn before and 1 h, 2 h, 3 h, 4 h, 6 h, 9 h and 12  h after drug administration. Patient and kidney survival rates were 100% at 1 year. At 6 months and 12 months creatinine clearance was 68.5±16.3 ml/min per 1.73 m2 and 64.0±15.2 ml/min per 1.73 m2 body surface area, respectively. Tacrolimus trough levels were 7.8±1.9 ng/ml and 7.3±2.5 ng/ml. The area under the concentration–time curve for 0 h to 12 h (AUC0–12) normalised to a dose of 0.15 mg/kg, increased with time from the kidney transplantation and stabilised after the 6th month post-transplantation. During the first month after transplantation the normalised tacrolimus concentration–time profiles were significantly greater in the older children (P<0.05); the actual doses were significantly greater in the younger children (P<0.05). In conclusion, initial doses of 0.15 mg/kg twice a day orally are safe and guarantee a satisfactory degree of immunosuppression, with our therapeutic regimen. Children <6 years old need to start with a 50% higher tacrolimus dose to achieve the same pharmacokinetic and immunosuppressive results.

Keywords

Kidney transplantation Pharmacokinetics Tacrolimus Children Acute rejection Chronic rejection 

References

  1. 1.
    Scott LJ, McKeage K, Keam SJ, Plosker GL (2003) Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63:1247–1297CrossRefGoogle Scholar
  2. 2.
    Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813–851CrossRefGoogle Scholar
  3. 3.
    Kershner RP, Fitzsimmons WE (1996) Relationship of TAC506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62:920–926CrossRefGoogle Scholar
  4. 4.
    Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A (2001) Clinical utility of monitoring tacrolimus blood concentrations in liver transplant recipients. J Clin Pharmacol 41:542–551CrossRefGoogle Scholar
  5. 5.
    Undre NA, van Hoff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, Kohnle M, Zanker B, Land W, Morales JM, Andres A, Schafer A, Stevenson P (1999) Low systematic exposure to tacrolimus correlates with acute rejection. Transplant Proc 31:296–298CrossRefGoogle Scholar
  6. 6.
    del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ (2002) Immunosuppressive therapy for pediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 41:115–135CrossRefGoogle Scholar
  7. 7.
    Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167CrossRefGoogle Scholar
  8. 8.
    Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in pediatric and adult recipients. Clin Pharmacokinet 40:283–295CrossRefGoogle Scholar
  9. 9.
    Wallemacq PE, Furlan V, Möller A, Schafer A, Stadler P, Firdaous I, Taburet AM, Reding R, Clement De Clety S, De Ville De Goyet J, Sokal E, Lykavieris L, Van Leeuw V, Bernard O, Otte JB, Undre NA (1998) Pharmacokinetics of tacrolimus (FH506) in pediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 23:367–370CrossRefGoogle Scholar
  10. 10.
    Shishido S, Asanuma H, Tajima E, Honda M, Nakai H (2001) Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 33:1066–1068CrossRefGoogle Scholar
  11. 11.
    Webb NJA, Stevenson PJ, Lewis MA, Postlethwaite RJ, Bradbury MG, Undre NA (2002) Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 34:1948–1950CrossRefGoogle Scholar
  12. 12.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G (2005) One year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int 18:36–42CrossRefGoogle Scholar
  13. 13.
    Racusen L, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachemberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713CrossRefGoogle Scholar
  14. 14.
    Dietemann J, Berthoux P (2001) Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. Nephrol Dial Transplant 16:2246–2249CrossRefGoogle Scholar
  15. 15.
    Alak AM, Lizak PP (1996) Quality assurance procedure for monitoring tacrolimus (TAC) concentration in whole blood by IMX assay. Ther Drug Monit 18:267–272CrossRefGoogle Scholar
  16. 16.
    Schwartz GJ, Haycock GB, Edelman CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259PubMedPubMedCentralGoogle Scholar
  17. 17.
    Fujisawa Healthcare. Prograf prescribing information [online]. https://doi.org/fujisawa.com/medinfo/pi/pi_pg.htm Accessed 21 June 2004
  18. 18.
    Venkataramanan R, Swaminathan A, Prasad T Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404–430CrossRefGoogle Scholar
  19. 19.
    Braun F, Schutz E, Peters B, Talaulicar R, Grupp C, Undre N, Schafer A, Armstrong VW, Oellerich M, Ringe B (2001) Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 33:2127–2128CrossRefGoogle Scholar
  20. 20.
    Bekersky I, Dressler D, Mekki Q (2001) Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 41:289–297CrossRefGoogle Scholar
  21. 21.
    Bekersky I, Dressler D, Mekki QA (2001) Effect of low and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 41:176–182CrossRefGoogle Scholar
  22. 22.
    van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP (2003) Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 16:721–725CrossRefGoogle Scholar
  23. 23.
    Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18:2409–2414CrossRefGoogle Scholar
  24. 24.
    Cooney GF, Habucky K, Hoppu K (1997) Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 32:481–495CrossRefGoogle Scholar
  25. 25.
    Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL (1991) Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 5:1–4CrossRefGoogle Scholar
  26. 26.
    Mochon M, Cooney G, Lum B, Caputo GC, Dunn S, Goldsmith B, Baluarte HJ, Polinsky MS, Kaiser BA (1996) Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 36:580–586CrossRefGoogle Scholar
  27. 27.
    Kahan BD (1985) Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40:457–476CrossRefGoogle Scholar
  28. 28.
    Filler G, Feber J, Lepage N, Weiler G, Mai I (2002) Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 6:411–418CrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Giovanni Montini
    • 1
    Email author
  • Francesca Ujka
    • 2
  • Cristina Varagnolo
    • 2
  • Luciana Ghio
    • 3
  • Fabrizio Ginevri
    • 4
  • Luisa Murer
    • 1
  • Basile S. Thafam
    • 2
  • Carla Carasi
    • 1
  • Graziella Zacchello
    • 1
  • Mario Plebani
    • 2
  1. 1.Nephrology, Dialysis and Transplant Unit, Pediatric DepartmentUniversity HospitalPaduaItaly
  2. 2.Department of Laboratory MedicineUniversity HospitalPaduaItaly
  3. 3.Nephrology, Dialysis and Transplant Unit, Pediatric DepartmentOspedale MaggioreMilanItaly
  4. 4.Nephrology, Dialysis and Transplant UnitGaslini HospitalGenoaItaly

Personalised recommendations